ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

ClinicalTrials.gov ID: NCT07277660

Public ClinicalTrials.gov record NCT07277660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 9, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis

Study identification

NCT ID
NCT07277660
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
UCB Biopharma SRL
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

  • Galvokimig Biological
  • Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2025
Primary completion
May 16, 2027
Completion
Mar 5, 2028
Last update posted
May 7, 2026

2025 – 2028

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Atd002 52021 Oceanside California 92056 Recruiting
Atd002 52008 Santa Monica California 90404 Recruiting
Atd002 52013 Boca Raton Florida 33486 Recruiting
Atd002 52007 Coral Gables Florida 33134 Recruiting
Atd002 52003 Miami Florida 33133 Recruiting
Atd002 52015 Savannah Georgia 31419 Recruiting
Atd002 52017 Chicago Illinois 60611 Recruiting
Atd002 52018 Wheaton Illinois 60189 Recruiting
Atd002 52012 New Albany Indiana 47150 Recruiting
Atd002 52014 Bowling Green Kentucky 42104 Recruiting
Atd002 52001 Troy Michigan 48084 Recruiting
Atd002 52009 Troy Michigan 48084 Recruiting
Atd002 52010 Omaha Nebraska 68144 Recruiting
Atd002 52020 The Bronx New York 10455 Recruiting
Atd002 52019 Philadelphia Pennsylvania 19114 Recruiting
Atd002 52005 Dallas Texas 75230 Recruiting
Atd002 52016 Frisco Texas 75033 Recruiting
Atd002 52011 Frisco Texas 75034 Recruiting
Atd002 52004 Sugar Land Texas 77479 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07277660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2026 · Synced May 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07277660 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →